Literature DB >> 16877724

The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.

Joanna B Madalinska1, Marc van Beurden, Eveline M A Bleiker, Heiddis B Valdimarsdottir, Judith Hollenstein, Leon F Massuger, Katja N Gaarenstroom, Marian J E Mourits, René H M Verheijen, Eleonora B L van Dorst, Hans van der Putten, Ko van der Velden, Henk Boonstra, Neil K Aaronson.   

Abstract

PURPOSE: Preventive health strategies for women at increased hereditary risk of ovarian cancer include gynecologic screening (GS) and/or prophylactic oophorectomy (PBSO). Hormone replacement therapy (HRT) is often prescribed to compensate for postsurgical endocrine deficiencies. This study examined the impact of HRT use on levels of endocrine symptoms and sexual functioning among premenopausal women who have undergone PBSO. Comparisons were made with similar women undergoing GS. PATIENTS AND METHODS: Questionnaire data on endocrine symptoms and sexual functioning were obtained from 450 premenopausal, high-risk women who had participated in this nationwide, cross-sectional, observational study.
RESULTS: Thirty-six percent of women had undergone PBSO and 64% had opted for GS. In the PBSO group, 47% of the women were current HRT users. They reported significantly fewer vasomotor symptoms than nonusers (P < .05). However, compared with premenopausal women undergoing GS, oophorectomized HRT users were more likely to report vasomotor symptoms (P < .01). HRT users and nonusers reported comparable levels of sexual functioning. Compared with women in the GS group, oophorectomized HRT users reported significantly more sexual discomfort due to vaginal dryness and dyspareunia (P < .01).
CONCLUSION: Although HRT has a positive impact on surgically induced vasomotor symptoms, it may be less effective than is often assumed. Symptom levels remain well above those of premenopausal women undergoing screening, and sexual discomfort is not alleviated by HRT. Physicians need to provide younger high-risk women considering PBSO with realistic information about both benefits and drawbacks of this preventive strategy, including information about premature menopause and HRT.

Entities:  

Mesh:

Year:  2006        PMID: 16877724     DOI: 10.1200/JCO.2005.05.1896

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  48 in total

Review 1.  Premature menopause or early menopause: long-term health consequences.

Authors:  Lynne T Shuster; Deborah J Rhodes; Bobbie S Gostout; Brandon R Grossardt; Walter A Rocca
Journal:  Maturitas       Date:  2009-09-05       Impact factor: 4.342

Review 2.  Long-term health consequences of premature or early menopause and considerations for management.

Authors:  S S Faubion; C L Kuhle; L T Shuster; W A Rocca
Journal:  Climacteric       Date:  2015-04-07       Impact factor: 3.005

Review 3.  Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.

Authors:  Roi Tschernichovsky; Annekathryn Goodman
Journal:  Oncologist       Date:  2017-03-17

4.  Factors affecting the decision to undergo risk-reducing salpingo-oophorectomy among women with BRCA gene mutation.

Authors:  Dongwon Kim; Eunyoung Kang; Euijun Hwang; Young Sun; Yoonsun Hwang; Cha Kyong Yom; Kidong Kim; Jae Hong No; Yong-Beom Kim; Sung-Won Kim
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

5.  The consequences of risk reducing salpingo-oophorectomy: the case for a coordinated approach to long-term follow up post surgical menopause.

Authors:  Carmel Pezaro; Paul James; Joanne McKinley; Mary Shanahan; Mary-Anne Young; Gillian Mitchell
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

6.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

7.  When Lowest Dose for Shortest Amount of Time Does Not Apply.

Authors:  Stephanie S Faubion; Julia A Files; Walter A Rocca
Journal:  J Womens Health (Larchmt)       Date:  2016-03-30       Impact factor: 2.681

Review 8.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  An Embryonic and Induced Pluripotent Stem Cell Model for Ovarian Granulosa Cell Development and Steroidogenesis.

Authors:  Shane Lipskind; Jennifer S Lindsey; Behzad Gerami-Naini; Jennifer L Eaton; Daniel O'Connell; Adam Kiezun; Joshua W K Ho; Nicholas Ng; Parveen Parasar; Michelle Ng; Michael Nickerson; Utkan Demirci; Richard Maas; Raymond M Anchan
Journal:  Reprod Sci       Date:  2017-08-31       Impact factor: 3.060

Review 10.  Breast cancer in young women and its impact on reproductive function.

Authors:  M Hickey; M Peate; C M Saunders; M Friedlander
Journal:  Hum Reprod Update       Date:  2009-01-27       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.